Crizotinib -- Benefit Assessment According to §35a Social Code Book V [Internet].

The aim of this report is to assess the added benefit of crizotinib in patients with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

http://ift.tt/2seTuZW